Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.70 |
| ▸ | CCND3 | P30281 | 2/20 | 0.57 |
| ▸ | CCNK | O75909 | 1/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | CCND2 | P30279 | 1/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16453394 | 0.88 | TNK2 (0.73) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL736688 | 0.83 | SYK (1.00) | SYK | |
| SCHEMBL4067264 | 0.81 | CCND3 (0.59) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL5520791 | 0.80 | SYK (0.62) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL4071068 | 0.78 | SYK (0.51) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL4067722 | 0.78 | SYK (0.58) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL17526200 | 0.77 | BRD4 (0.70) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL1979124 | 0.77 | CCND3 (0.55) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL5522245 | 0.77 | CCND3 (0.57) | SYKCCND3CCNKCCNA2CDK2 | |
| SCHEMBL30306406 | 0.76 | BRD4 (0.74) | CCND3CCNKCCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | SYK 2974/4885CCND3 32/4885CCNK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.